A detailed history of Capital International LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital International LTD holds 74,692 shares of BGNE stock, worth $15.1 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares
74,692
Previous 74,874 0.24%
Holding current value
$15.1 Million
Previous $11.7 Million 8.99%
% of portfolio
0.51%
Previous 0.58%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$129.52 - $174.32 $23,572 - $31,726
-182 Reduced 0.24%
74,692 $10.7 Million
Q1 2024

May 14, 2024

BUY
$141.8 - $181.47 $1.31 Million - $1.67 Million
9,213 Added 14.03%
74,874 $11.7 Million
Q4 2023

Feb 13, 2024

BUY
$158.67 - $201.58 $330,033 - $419,286
2,080 Added 3.27%
65,661 $11.8 Million
Q3 2023

Nov 13, 2023

SELL
$179.87 - $225.13 $71,408 - $89,376
-397 Reduced 0.62%
63,581 $11.4 Million
Q2 2023

Aug 11, 2023

BUY
$178.3 - $266.78 $113,933 - $170,472
639 Added 1.01%
63,978 $11.4 Million
Q1 2023

May 15, 2023

BUY
$215.53 - $274.5 $757,372 - $964,593
3,514 Added 5.87%
63,339 $13.7 Million
Q4 2022

Feb 14, 2023

BUY
$125.51 - $229.3 $603,326 - $1.1 Million
4,807 Added 8.74%
59,825 $13.2 Million
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $786,977 - $1.21 Million
5,971 Added 12.17%
55,018 $7.42 Million
Q2 2022

Aug 15, 2022

BUY
$121.11 - $216.05 $80,538 - $143,673
665 Added 1.37%
49,047 $7.94 Million
Q4 2021

Feb 14, 2022

BUY
$248.56 - $389.34 $4,474 - $7,008
18 Added 0.04%
48,382 $13.1 Million
Q3 2021

Nov 15, 2021

BUY
$249.6 - $403.14 $464,505 - $750,243
1,861 Added 4.0%
48,364 $17.6 Million
Q2 2021

Aug 16, 2021

SELL
$292.75 - $367.01 $283,674 - $355,632
-969 Reduced 2.04%
46,503 $16 Million
Q1 2021

May 14, 2021

SELL
$260.64 - $382.12 $1.22 Million - $1.79 Million
-4,694 Reduced 9.0%
47,472 $16.5 Million
Q4 2020

Feb 16, 2021

SELL
$221.31 - $316.61 $2.62 Million - $3.74 Million
-11,823 Reduced 18.48%
52,166 $13.5 Million
Q3 2020

Nov 13, 2020

BUY
$189.18 - $286.44 $2.52 Million - $3.81 Million
13,318 Added 26.28%
63,989 $18.3 Million
Q2 2020

Aug 14, 2020

BUY
$123.9 - $195.41 $71,242 - $112,360
575 Added 1.15%
50,671 $9.55 Million
Q1 2020

May 15, 2020

BUY
$121.84 - $173.19 $6.1 Million - $8.68 Million
50,096 New
50,096 $6.17 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $21B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Capital International LTD Portfolio

Follow Capital International LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International LTD , based on Form 13F filings with the SEC.

News

Stay updated on Capital International LTD with notifications on news.